No FDA-approved generic exists for Zepbound, Mounjaro, Wegovy or Ozempic as of November 15, 2026, generic liraglutide (Victoza and Saxenda) does exist, and brand-name cash prices start at $149 a month for the Wegovy pill at 1.5 mg and $299 for Zepbound at 2.5 mg.
No insurance needed. Two programs to check.
Eden$99 a monthWeight loss warranty includedCheck price →
Collective$59 a month, drug priceLowest price on our chartCheck price →
Which GLP-1s have a generic today
| Brand | FDA-approved generic |
|---|---|
| Zepbound and Mounjaro Tirzepatide | No. No generic is approved. A patent on tirzepatide itself runs to May 13, 2036 on FDA's list. |
| Wegovy and Ozempic Semaglutide | No. No generic is approved. Apotex holds a tentative approval dated April 7, 2026, which does not allow it to sell. A patent on semaglutide itself runs to December 5, 2031 on FDA's list. |
| Saxenda Liraglutide, daily | Yes. FDA approved Teva's generic for weight loss on August 27, 2025. |
| Victoza Liraglutide, daily | Yes. FDA approved the first generic, from Hikma, on December 23, 2024, for type 2 diabetes. |
| Byetta Exenatide | Yes. FDA approved Amneal's generic on November 19, 2024. Its record now lists the product as discontinued. |
Read on FDA's Drugs@FDA and Orange Book records, November 15, 2026.
Why there is no generic Zepbound, Mounjaro, Wegovy or Ozempic
A generic is a copy the FDA has approved. The maker has to show its version delivers the same amount of the active ingredient as the brand, at the same strength and in the same form. The FDA holds back final approval of a generic until the brand's patent and exclusivity questions are settled.
Both medicines are still under patent. FDA's Orange Book lists a patent on semaglutide itself, the medicine in Wegovy and Ozempic, that expires on December 5, 2031. It lists one on tirzepatide, the medicine in Zepbound and Mounjaro, that expires on May 13, 2036. Other patents on the same lists run later.
One company is waiting. Apotex's generic semaglutide injection got a tentative approval on April 7, 2026. FDA gives that when a generic is ready before the patents end, and it does not allow the company to sell. Drugs@FDA lists no approved or tentatively approved generic of tirzepatide.
Generic liraglutide, the GLP-1 that does have one
Liraglutide is the older daily injection Novo Nordisk sells as Victoza for type 2 diabetes and Saxenda for weight loss. FDA approved the first generic of Victoza, from Hikma, on December 23, 2024. It approved Teva's liraglutide, which carries the weight loss use, on August 27, 2025.
Novo Nordisk is discontinuing Saxenda, with its last shipments to wholesalers in late January 2027. The generics are separate products from other makers.
Liraglutide is not semaglutide or tirzepatide. It is injected every day, and its label is its own: GLP-1 dosing has each drug's steps. We do not track a cash price for generic liraglutide, so none is printed here.
Compounded semaglutide and tirzepatide are not generics
No FDA-approved generic of either medicine exists, so a product sold as generic Ozempic or generic Zepbound is not one. Programs on our chart sell compounded semaglutide and compounded tirzepatide instead. A licensed pharmacy makes a compounded drug against a prescription. The FDA has not approved it, and does not review it for safety, effectiveness or quality before it is sold. A generic has passed that review.
Compounded is where the lowest cash prices are. Compounded semaglutide costs from $59 a month at Collective (drug price, plus a yearly membership), or $79 at CoreAge Rx with no yearly membership. Compounded tirzepatide costs from $69 a month at Collective (drug price, plus a yearly membership), or $129 at Eden with no yearly membership. The programs that prescribe each are on compounded GLP-1 by medication.
What the cheapest options cost today
| Medication | Cash price a month |
|---|---|
| Compounded semaglutide | From $59 a month at Collective (drug price, plus a yearly membership), or $79 at CoreAge Rx with no yearly membership |
| Compounded tirzepatide | From $69 a month at Collective (drug price, plus a yearly membership), or $129 at Eden with no yearly membership |
| Wegovy pill, from NovoCare | $149 at 1.5 mg, $199 at 4 mg and $299 at 9 mg and 25 mg |
| Wegovy pen, from NovoCare | $349 a month for the pen and $399 for the 7.2 mg HD pen |
| Zepbound, from LillyDirect | $299 at 2.5 mg, $399 at 5 mg and $449 to $699 at 7.5 mg and up |
| Ozempic pen, from NovoCare | $349 to $499 a month by dose |
| Mounjaro pen, from LillyDirect | $499 a month |
Prices are the sellers' own, checked November 16, 2026. Every row needs a prescription, and no row is a generic.
Questions people ask
Is there a generic Zepbound?
Is there a generic Mounjaro?
Is there a generic Wegovy?
Is there a generic Ozempic?
Is compounded semaglutide a generic?
Compare GLP-1 medications
- Tirzepatide vs semaglutide cost
- Mounjaro vs Zepbound
- More on generic Ozempic
- Every GLP-1 medication side by side
Sources
Evidence checked November 15, 2026
Every figure above is taken from the document beside it, the FDA label or the trial that produced it, so you can read the source instead of trusting us. How we check sources.
15 documents
- What a generic drug is and what its maker has to show the FDAGeneric drugs: questions and answers (FDA)
- The first generic of Victoza (liraglutide), approved December 23, 2024, and the earlier generic of ByettaFDA approves first generic of once-daily GLP-1 injection (FDA news release)
- Teva's generic liraglutide, approved August 27, 2025Drugs@FDA, ANDA 214568
- That generic's approved use: weight loss, with diet and exercisePrescribing information for liraglutide injection, Teva (DailyMed)
- Amneal's generic exenatide, approved November 19, 2024, now listed as discontinuedDrugs@FDA, ANDA 206697
- Apotex's generic semaglutide injection, tentative approval April 7, 2026Drugs@FDA, ANDA 220314
- What a tentative approval is: it does not allow the applicant to market the genericDrugs@FDA glossary of terms (FDA)
- The semaglutide patent that expires December 5, 2031, listed for OzempicOrange Book patent listing, Ozempic (FDA)
- The same patent and date, listed for WegovyOrange Book patent listing, Wegovy (FDA)
- The tirzepatide patent that expires May 13, 2036, listed for MounjaroOrange Book patent listing, Mounjaro (FDA)
- The same patent and date, listed for ZepboundOrange Book patent listing, Zepbound (FDA)
- Every FDA application for semaglutide: Novo Nordisk's own, and the one tentative approvalDrugs@FDA records for semaglutide (openFDA)
- Every FDA application for tirzepatide: Eli Lilly's two, and no genericDrugs@FDA records for tirzepatide (openFDA)
- The FDA has not approved compounded drugs and does not review them before they are soldFDA's concerns with unapproved GLP-1 drugs used for weight loss (FDA)
- Saxenda's discontinuation and the last shipments to wholesalersSaxenda discontinuation notice (Novo Nordisk)
Prices from the programs' own pages, NovoCare and LillyDirect, checked November 16. How we check prices.